Showing results (261-270 of 503) with videos related to
Sort By:
Pageof 51
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 12, 2021
Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trialBianca Weinstock-Guttman, Robert Bermel, Gary Cutter, et al.Neurology|February 29, 2020
Education Research: Multiple sclerosis and neuroimmunology fellowship training status in the United StatesAhmed Z Obeidat, Yasir N Jassam, Le H Hua, et al.BMJ Neurology Open|June 3, 2021
Acute flaccid myelitis: long-term outcomes recorded in the CAPTURE study compared with paediatric transverse myelitisBenjamin Greenberg, Patricia Plumb, Gary Cutter, et al.Pediatrics|October 21, 2009
Clinical and economic effects of iNO in premature newborns with respiratory failure at 1 yearR Scott Watson, Gilles Clermont, John P Kinsella, et al.Journal of Neurology, Neurosurgery, and Psychiatry|January 28, 2026
Breaking the PROMISE: poor association between brain volume loss and clinical disability worsening over 2 years of follow-up in primary progressive multiple sclerosisMarcus Koch, Jop Mostert, Eva M Strijbis, et al.Genetic Epidemiology|October 21, 2021
Mendelian randomization in the multivariate general linear model frameworkPhillip H Allman, Inmaculada Aban, Dustin M Long, et al.Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging|November 6, 2014
Identifying the start of multiple sclerosis injury: a serial DTI studyDaniel Ontaneda, Ken Sakaie, Jian Lin, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|August 2, 2019
Perspectives of individuals with multiple sclerosis on discontinuation of disease-modifying therapiesMarisa P McGinley, Philip A Cola, Robert J Fox, et al.BMJ Neurology Open|January 9, 2026
Evaluation of cortical pathology in primary-progressive multiple sclerosis: a post hoc analysis of the SPRINT-MS trialEva A Krijnen, Anne M Bruijn, Ani Eloyan, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|June 29, 2004
Mitoxantrone as a potential therapy for primary progressive multiple sclerosisOlaf Stüve, Mariko Kita, Daniel Pelletier, et al.Pageof 51